JP2014510148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510148A5 JP2014510148A5 JP2014503994A JP2014503994A JP2014510148A5 JP 2014510148 A5 JP2014510148 A5 JP 2014510148A5 JP 2014503994 A JP2014503994 A JP 2014503994A JP 2014503994 A JP2014503994 A JP 2014503994A JP 2014510148 A5 JP2014510148 A5 JP 2014510148A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- propane
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 41
- -1 fluoromethylene Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 7
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 claims description 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- SCDDZPIYMIUTKB-UHFFFAOYSA-N 2-methyl-n-propylpropane-2-sulfinamide Chemical compound CCCNS(=O)C(C)(C)C SCDDZPIYMIUTKB-UHFFFAOYSA-N 0.000 claims description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 4
- SQBCGUPFPORBQY-UHFFFAOYSA-N n-ethylethanesulfonamide Chemical group CCNS(=O)(=O)CC SQBCGUPFPORBQY-UHFFFAOYSA-N 0.000 claims description 4
- IWKQAMIEEPSFOV-UHFFFAOYSA-N n-propylcyclopropanesulfonamide Chemical compound CCCNS(=O)(=O)C1CC1 IWKQAMIEEPSFOV-UHFFFAOYSA-N 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- CFJZAIYRSLDQRS-UHFFFAOYSA-N 2,2-dimethyl-n-propylpropanamide Chemical group CCCNC(=O)C(C)(C)C CFJZAIYRSLDQRS-UHFFFAOYSA-N 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- LZKPMNCTFKUWIX-UHFFFAOYSA-N 2-methyl-n-propylpropane-1-sulfonamide Chemical compound CCCNS(=O)(=O)CC(C)C LZKPMNCTFKUWIX-UHFFFAOYSA-N 0.000 claims description 2
- UHJSCAISWCWDBF-UHFFFAOYSA-N 2-methyl-n-propylpropane-2-sulfonamide Chemical compound CCCNS(=O)(=O)C(C)(C)C UHJSCAISWCWDBF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical group CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 2
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical group CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 229940047889 isobutyramide Drugs 0.000 claims description 2
- BRQMYUTYTCOSRF-UHFFFAOYSA-N n-(2-methylpropyl)ethanesulfonamide Chemical compound CCS(=O)(=O)NCC(C)C BRQMYUTYTCOSRF-UHFFFAOYSA-N 0.000 claims description 2
- ZLDNEQSZADTPOP-UHFFFAOYSA-N n-cyclopropylethanesulfonamide Chemical compound CCS(=O)(=O)NC1CC1 ZLDNEQSZADTPOP-UHFFFAOYSA-N 0.000 claims description 2
- ICMYVGUJSCZEMG-UHFFFAOYSA-N n-ethyl-2,2-dimethylpropanamide Chemical compound CCNC(=O)C(C)(C)C ICMYVGUJSCZEMG-UHFFFAOYSA-N 0.000 claims description 2
- WQLQCNJDXCGKIL-UHFFFAOYSA-N n-ethyl-2-methylpropanamide Chemical compound CCNC(=O)C(C)C WQLQCNJDXCGKIL-UHFFFAOYSA-N 0.000 claims description 2
- ITAVVRIUCHRIOY-UHFFFAOYSA-N n-ethyl-2-methylpropane-1-sulfonamide Chemical compound CCNS(=O)(=O)CC(C)C ITAVVRIUCHRIOY-UHFFFAOYSA-N 0.000 claims description 2
- APYPAHZSEYKDJK-UHFFFAOYSA-N n-ethyl-2-methylpropane-2-sulfinamide Chemical compound CCNS(=O)C(C)(C)C APYPAHZSEYKDJK-UHFFFAOYSA-N 0.000 claims description 2
- SEOJZIBDCWVWLZ-UHFFFAOYSA-N n-ethyl-2-methylpropane-2-sulfonamide Chemical compound CCNS(=O)(=O)C(C)(C)C SEOJZIBDCWVWLZ-UHFFFAOYSA-N 0.000 claims description 2
- BOQSOBHPGBKUJL-UHFFFAOYSA-N n-ethyl-3-methylbutanamide Chemical compound CCNC(=O)CC(C)C BOQSOBHPGBKUJL-UHFFFAOYSA-N 0.000 claims description 2
- WLQCOYYCNXROKF-UHFFFAOYSA-N n-ethylcyclopropanecarboxamide Chemical compound CCNC(=O)C1CC1 WLQCOYYCNXROKF-UHFFFAOYSA-N 0.000 claims description 2
- SPUYBKOXLLVWFR-UHFFFAOYSA-N n-ethylcyclopropanesulfonamide Chemical compound CCNS(=O)(=O)C1CC1 SPUYBKOXLLVWFR-UHFFFAOYSA-N 0.000 claims description 2
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 claims description 2
- PZVFQOBASICMME-UHFFFAOYSA-N n-ethylmethanesulfonamide Chemical compound CCNS(C)(=O)=O PZVFQOBASICMME-UHFFFAOYSA-N 0.000 claims description 2
- ABMDIECEEGFXNC-UHFFFAOYSA-N n-ethylpropanamide Chemical compound CCNC(=O)CC ABMDIECEEGFXNC-UHFFFAOYSA-N 0.000 claims description 2
- CDXKRTQZEPXTCV-UHFFFAOYSA-N n-ethylpropane-2-sulfonamide Chemical compound CCNS(=O)(=O)C(C)C CDXKRTQZEPXTCV-UHFFFAOYSA-N 0.000 claims description 2
- QSPPRYLTQFCUCH-UHFFFAOYSA-N n-methylethanesulfonamide Chemical group CCS(=O)(=O)NC QSPPRYLTQFCUCH-UHFFFAOYSA-N 0.000 claims description 2
- DUIVBXGYYJPSJX-UHFFFAOYSA-N n-methylpropane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC DUIVBXGYYJPSJX-UHFFFAOYSA-N 0.000 claims description 2
- QKYMUUKIEKQBFW-UHFFFAOYSA-N n-propan-2-ylethanesulfonamide Chemical group CCS(=O)(=O)NC(C)C QKYMUUKIEKQBFW-UHFFFAOYSA-N 0.000 claims description 2
- ATADNMCXCXUSOW-UHFFFAOYSA-N n-propylcyclopropanecarboxamide Chemical group CCCNC(=O)C1CC1 ATADNMCXCXUSOW-UHFFFAOYSA-N 0.000 claims description 2
- IBMVWPYCKNHSRA-UHFFFAOYSA-N n-propylethanesulfonamide Chemical compound CCCNS(=O)(=O)CC IBMVWPYCKNHSRA-UHFFFAOYSA-N 0.000 claims description 2
- AKVITZDRJGIFAS-UHFFFAOYSA-N n-propylmethanesulfonamide Chemical compound CCCNS(C)(=O)=O AKVITZDRJGIFAS-UHFFFAOYSA-N 0.000 claims description 2
- OOPVMFMDPJFBFN-UHFFFAOYSA-N n-propylpropane-2-sulfonamide Chemical compound CCCNS(=O)(=O)C(C)C OOPVMFMDPJFBFN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 0 *c1c(*c2nc3c(N)nc(*)nc3[n]2*)cc2OCOc2c1 Chemical compound *c1c(*c2nc3c(N)nc(*)nc3[n]2*)cc2OCOc2c1 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472061P | 2011-04-05 | 2011-04-05 | |
| US61/472,061 | 2011-04-05 | ||
| PCT/US2012/032371 WO2012138894A1 (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016228549A Division JP2017061540A (ja) | 2011-04-05 | 2016-11-25 | Ｈｓｐ９０阻害物質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510148A JP2014510148A (ja) | 2014-04-24 |
| JP2014510148A5 true JP2014510148A5 (enExample) | 2015-05-21 |
| JP6266506B2 JP6266506B2 (ja) | 2018-01-24 |
Family
ID=48166734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014503994A Expired - Fee Related JP6266506B2 (ja) | 2011-04-05 | 2012-04-05 | Ｈｓｐ９０阻害物質 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9346808B2 (enExample) |
| EP (1) | EP2694505B1 (enExample) |
| JP (1) | JP6266506B2 (enExample) |
| KR (1) | KR102010222B1 (enExample) |
| CN (1) | CN103582642B (enExample) |
| AU (1) | AU2012240077C1 (enExample) |
| BR (1) | BR112013025634A2 (enExample) |
| CA (1) | CA2832530C (enExample) |
| EA (1) | EA201391334A1 (enExample) |
| MX (1) | MX360390B (enExample) |
| WO (1) | WO2012138894A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2006084030A2 (en) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| EP3305297A1 (en) | 2006-06-30 | 2018-04-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases through inhibition of hsp90 |
| CA2776308C (en) | 2009-10-07 | 2020-01-28 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| JP6266506B2 (ja) | 2011-04-05 | 2018-01-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害物質 |
| US9546170B2 (en) | 2011-04-05 | 2017-01-17 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| EP3208615B1 (en) * | 2011-07-08 | 2019-10-09 | Sloan Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| AU2014306417C1 (en) | 2013-08-16 | 2019-07-25 | Memorial Sloan-Kettering Cancer Center | Selective Grp94 inhibitors and uses thereof |
| US9994573B2 (en) * | 2013-12-23 | 2018-06-12 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| MA40535A (fr) | 2014-09-17 | 2016-03-24 | Memorial Sloan Kettering Cancer Center | Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 |
| KR20180058824A (ko) | 2015-10-05 | 2018-06-01 | 메모리얼 슬로안-케터링 캔서 센터 | 암 치료를 위한 합리적 병용 요법 |
| TW201919613A (zh) * | 2017-06-23 | 2019-06-01 | 美商薩沐斯醫療公司 | 用於創傷性腦損傷及其後遺症之表伴護蛋白體(epichaperome)抑制劑療法 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670348B1 (en) | 1997-05-14 | 2003-12-30 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| WO2000061578A1 (en) | 1999-04-09 | 2000-10-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| KR100850727B1 (ko) | 2000-11-02 | 2008-08-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에이치에스피90에 결합하기 위한 소분자 조성물 |
| JP2005505506A (ja) | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な大環状分子 |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| EP1450784A4 (en) | 2001-11-09 | 2005-02-09 | Conforma Therapeutics Corp | HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE |
| MXPA04008312A (es) | 2002-02-28 | 2004-11-26 | Astrazeneca Ab | Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos. |
| CA2522700A1 (en) | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| EA010160B1 (ru) | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2006084030A2 (en) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| CA2634723A1 (en) * | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
| US7595401B2 (en) | 2006-05-12 | 2009-09-29 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in cancer |
| EP3305297A1 (en) | 2006-06-30 | 2018-04-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases through inhibition of hsp90 |
| JP2010502743A (ja) | 2006-09-11 | 2010-01-28 | キュリス，インコーポレイテッド | 抗増殖薬剤としての多機能性低分子 |
| FR2906824B1 (fr) | 2006-10-09 | 2008-12-26 | Roger Mondelin Sas Soc Par Act | Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| US20080234297A1 (en) | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| DK2069324T3 (da) * | 2007-03-20 | 2013-09-02 | Curis Inc | Fusioneret aminopyridin som hsp90-inhibitorer |
| US20100240656A1 (en) * | 2007-07-12 | 2010-09-23 | Oryzon Genomics, S.A. | Compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| JP2011503206A (ja) | 2007-11-14 | 2011-01-27 | ミレクシス， インコーポレイテッド | 疾患および障害の治療における治療化合物およびその使用方法 |
| MX2011007612A (es) | 2009-01-16 | 2012-01-20 | Curis Inc | Aminopiridinas fusionadas para el tratamiento de tumores del cerebro. |
| GB0905328D0 (en) * | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
| PL2453989T3 (pl) * | 2009-07-17 | 2020-05-18 | Cleanspace Ip Pty Ltd. | Maska oddechowa |
| GB0914543D0 (en) * | 2009-08-20 | 2009-09-30 | Ge Healthcare Ltd | Radioiodination method |
| CA2776308C (en) | 2009-10-07 | 2020-01-28 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| US9546170B2 (en) | 2011-04-05 | 2017-01-17 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| JP6266506B2 (ja) | 2011-04-05 | 2018-01-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害物質 |
| AU2014306417C1 (en) | 2013-08-16 | 2019-07-25 | Memorial Sloan-Kettering Cancer Center | Selective Grp94 inhibitors and uses thereof |
-
2012
- 2012-04-05 JP JP2014503994A patent/JP6266506B2/ja not_active Expired - Fee Related
- 2012-04-05 AU AU2012240077A patent/AU2012240077C1/en not_active Ceased
- 2012-04-05 US US14/009,976 patent/US9346808B2/en active Active
- 2012-04-05 CA CA2832530A patent/CA2832530C/en active Active
- 2012-04-05 EA EA201391334A patent/EA201391334A1/ru unknown
- 2012-04-05 BR BR112013025634A patent/BR112013025634A2/pt not_active IP Right Cessation
- 2012-04-05 WO PCT/US2012/032371 patent/WO2012138894A1/en not_active Ceased
- 2012-04-05 EP EP12717520.6A patent/EP2694505B1/en active Active
- 2012-04-05 KR KR1020137029259A patent/KR102010222B1/ko not_active Expired - Fee Related
- 2012-04-05 MX MX2013011532A patent/MX360390B/es active IP Right Grant
- 2012-04-05 CN CN201280027256.0A patent/CN103582642B/zh not_active Expired - Fee Related
-
2016
- 2016-05-20 US US15/160,293 patent/US9926321B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |